Berkeley Catalyst Fund has helped close a $90m series B round for 4D Molecular Therapeutics, which emerged out of UC Berkeley.
4D Molecular Therapeutics (4DMT), a US-based gene therapy spinout of University of California (UC) Berkeley, closed a $90m series B round yesterday featuring university venture fund Berkeley Catalyst Fund.
Pharmaceutical firms Chiesi Group and Pfizer and muscular dystrophy-focused non-profit CureDuchenne participated in the round through respective investment units Chiesi Ventures, which is managed by Pappas Capital, Pfizer Ventures and CureDuchenne Ventures.
Hedge fund Viking Global Investors led the round, which further included ArrowMark Partners, Janus Henderson Investors, Biotechnology…
